Turkish Journal of Biology
Abstract
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.
DOI
10.3906/biy-2005-91
Keywords
SARS-CoV-2, COVID-19, neutralizing antibodies, human monoclonal antibody, display technologies, human scFv, neutralizing assays, animal models
First Page
203
Last Page
214
Recommended Citation
BALCIOĞLU, B. K, ÖNCÜ, M. D, ÖZTÜRK, H. Ü, YÜCEL, F, KAYA, F, SERHATLI, M, POLAT, H. Ü, TEKİN, Ş, & BAHADIR, A. Ö (2020). SARS-CoV-2 neutralizing antibody development strategies. Turkish Journal of Biology 44 (7): 203-214. https://doi.org/10.3906/biy-2005-91
